Pacific Biosciences of California PACB Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's change in accrued liabilities?
- Pacific Biosciences of California (PACB) reported change in accrued liabilities of $314K in Q1 2026.
- How has Pacific Biosciences of California's change in accrued liabilities changed year-over-year?
- Pacific Biosciences of California's change in accrued liabilities increased by 1.0% year-over-year, from $311K to $314K.
- What is the long-term trend for Pacific Biosciences of California's change in accrued liabilities?
- Over 2 years (2021 to 2025), Pacific Biosciences of California's change in accrued liabilities has grown at a -54.6% compound annual growth rate (CAGR), from $15.32M to $3.16M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.